Replies to post #5956 on GTC Biotherapeutics (fka GTCB)

[jessellivermore]

Not to be critical, but Atryn tends to lower the risk of DVT

[DewDiligence]

Re: Efficacy endpoint of US Atryn trial

The primary efficacy endpoint of the US ATryn trial is symptomatic DVT—not merely DVT observable with a diagnostic scan. Thus, the US trial has a more favorable endpoint for GTC than the “any DVT” endpoint used in the trial that supported EU approval.